



MOREPEN



Date: 10/11/2021

To,

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Symbol: MOREPENLAB

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Scrip Code: 500288

Subject: Intimation of Post Results (Q2-FY 2021-22) Conference Call

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, *as amended*, we would like to inform you that subsequent to the declaration of unaudited standalone and consolidated financial results for the quarter and half year ended 30th September, 2021, the Company is organizing an 'Analyst/ Investor Conference Call' on **Thursday, 11th November, 2021 at 04:00 P.M. (IST)**.

The details of the conference call are attached herewith.

This is for your information and records.

Thanking you.

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava
Company Secretary



Encl.: As Above

Morepen Laboratories Limited

CIN: L24231 HP1984PLC006028

Plant & Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205

Tel.: +91-1795-266401-03, 244590, Fax: +91-1795-244591, E-mail: plants@morepen.com,

Website: www.morepen.com

MOREPEN LABORATORIES LTD.
ANALYST / INVESTOR CONFERENCE CALL
Q2 FY 2022 RESULT

Morepen Laboratories Limited, financial results for the second quarter ended September 30, 2021 are scheduled to be announced on Thursday, November 11, 2021. A copy of the results will be posted on the company website www.morepen.com

The company is hosting an Analyst / Investor Conference Call to discuss the financial performance of the company. Details of the conference call are as follows:

Date: Thursday, 11th November 2021

Time: 04:00 PM – 05:00 PM IST

India Access Numbers	
Local Access / Universal Access (Available all over India)	+91 22 6280 1102 +91 22 7115 8003
International Access Numbers	
USA Toll Free	18667462133
UK Toll Free	08081011573
HK Toll Free	800964448
Singapore Toll Free	8001012045

Join with DiamondPass™ No Wait Time

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=6661268&linkSecurityString=1a38cc3a5c>

The following senior management of the company would participate in the conference:

Mr. Sushil Suri, Chairman & Managing Director

Mr. Ajay Sharma, Chief Financial Officer

Mr. Vipul Kumar Srivastava, Company Secretary

About Morepen Laboratories Ltd. (www.morepen.com)

NSE: MOREPENLAB, BSE: 500288

Morepen Laboratories Ltd. is a 36-year-old, around Rs. 1,200 Cr. pharmaceutical and healthcare products company. The company went public in the year 1992 and is currently listed at both the Bombay Stock Exchange (BSE) as well as the National Stock Exchange (NSE).

Morepen is a leading manufacturer of high-quality APIs, Home Diagnostics, Formulations and OTC products in north India. All the manufacturing facilities of the company are in the state of Himachal Pradesh and meet the latest international standards. Company's both API facilities at Masulkhana and Baddi are approved by USFDA and other regulatory bodies of Europe, Asia, and Australia. The company's state-of-the-art manufacturing facility at Baddi comprises a scientifically integrated complex of 10 plants, each with a specific product profile.

Amongst several APIs manufactured by Morepen, the company is the largest manufacturer of Loratadine and Montelukast (anti-allergy and anti-asthmatic drugs). It also enjoys a significant share for Atorvastatin and Rosuvastatin (Cholesterol reducing drugs) in the international market. Besides, the company has established an extensive footprint for its API products on the strength of quality, documentation and consistency in regulatory compliances, both in the domestic as well as global markets. Morepen has achieved to its credit the enduring confidence of a strong (over 1250) customer base spanning over 80 countries for its leading API products.

In line with its vision of keeping pace with the changing landscape, Morepen continues to invest in its Research and Development (R&D) infrastructure aimed at developing new molecules to deliver the latest drugs at competitive prices in the global markets. The company's strong dedicated R&D team has successfully developed 22 products in last three years out of which 12 products have already been commercialized. The company has also started supplying these new products to customers with complete documentation like DMF, tech packs and other regulatory compliances.

Morepen's R&D Centre meets all the global regulatory requirements and was recently approved by Department of Scientific & Industrial Research, Govt of India, New Delhi. Morepen R&D and QA team, known for its impeccable service, has filed 125 Patents, 60 DMFs and 8 CEPs for USA and Europe, Japan, China, Taiwan and Australian markets.

Morepen is also an established name in home diagnostics sector which remained untapped for a long time in India. Dr. Morepen has gained No.1 position in manufacturing and marketing of Blood Glucose Monitors in India, displacing some established multinational players. With a stable base of more than four million installations of Blood Glucose Monitors, the company has an installed base of over 10 million Glucose meters and has sold more than 600 million glucometer strips (single tests) till date. Dr. Morepen also has a formidable presence and is the leader in the Blood Pressure Monitors and Nebulizers segments in the domestic market. Latest addition of Oximeter and Oxygen Concentrators has placed company in limelight due to exploding pandemic.



Brand Dr. Morepen, which was launched way back in 2001, has created a niche for itself in over the counter (OTC) and Self-Health segment products as well. Dr. Morepen has reached all over the country with over 50 products including famous brands like 'Burnol' and 'Lemolate'.

For Further Details, please contact:

Investors Relations Team:

Ashu Dutt

ADG Institutional Investor Relations

ashuduttir@gmail.com +919619647788

Public Relations Team:

Arun Thankappan | arun.thankappan@adfactorspr.com | +919930860706